Vaccine Diplomacy : 34 Countries In Queue To Receive Covid Vaccines, Informs EAM Jaishankar swarajyamag.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from swarajyamag.com Daily Mail and Mail on Sunday newspapers.
New Delhi, March 1 (IANS) The coronavirus vaccine - one of the worlds most in-demand commodities - has become a new currency for international diplomacy, in which India seems to be having an upper hand over its competitor China.
Dr Gangandeep Kang, noted vaccine expert and AIDAN have questioned the claim that Covaxin would work against the UK strain of Covid pointing out that there was no data or scientific basis to back the claim. What is the local efficacy data on the basis of which the expert committee recommended approval for the two vaccines? It is shocking that while Bharat Biotech is struggling to complete recruitment of volunteers for phase-3 trial, the approval was given. So what did the SEC base the approval on? asked Dr Amar Jesani, editor of the Indian Journal of Medical Ethics. We need to wait for at least the early results from that Bharat Biotech phase-3 trial before approval. Yes, there is a pandemic, and we need vaccines. But it is equally important that the public have absolute trust in a vaccine that is approved, said Dr JN Rao, an independent public health physician, researcher, and visiting professor at Staffordshire University.